<SEC-DOCUMENT>0001193125-25-242909.txt : 20251020
<SEC-HEADER>0001193125-25-242909.hdr.sgml : 20251020
<ACCEPTANCE-DATETIME>20251020060141
ACCESSION NUMBER:		0001193125-25-242909
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251018
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251020
DATE AS OF CHANGE:		20251020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		251402222

	BUSINESS ADDRESS:	
		STREET 1:		566 QUEENSBURY AVENUE
		CITY:			QUEENSBURY
		STATE:			NY
		ZIP:			12804
		BUSINESS PHONE:		(518) 743-8892

	MAIL ADDRESS:	
		STREET 1:		566 QUEENSBURY AVENUE
		CITY:			QUEENSBURY
		STATE:			NY
		ZIP:			12804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d51469d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dcth="http://www.delcath.com/20251018" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2025-10-18_to_2025-10-18">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-581">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-10-18_to_2025-10-18">0000872912</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="dcth-20251018.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-10-18_to_2025-10-18"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872912</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-10-18</xbrli:startDate> <xbrli:endDate>2025-10-18</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, DC 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-592">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-10-18_to_2025-10-18" format="ixt:datemonthdayyearen" id="ixv-593">October&#160;18, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-594">DELCATH SYSTEMS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-10-18_to_2025-10-18" format="ixt-sec:stateprovnameen" id="ixv-595">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-596">001-16133</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-597">06-1245881</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation or organization)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-598">566 Queensbury Avenue</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-599">Queensbury</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-600">NY</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-601">12804</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices) (Zip Code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-602">(212)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-603">489-2100</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-10-18_to_2025-10-18" format="ixt-sec:boolballotbox" id="ixv-604">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-10-18_to_2025-10-18" format="ixt-sec:boolballotbox" id="ixv-605">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-10-18_to_2025-10-18" format="ixt-sec:boolballotbox" id="ixv-606">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-10-18_to_2025-10-18" format="ixt-sec:boolballotbox" id="ixv-607">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-608">Common Stock, $.01 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-609">DCTH</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR <span style="white-space:nowrap">&#167;240.12b-2).</span></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-10-18_to_2025-10-18" format="ixt-sec:boolballotbox" id="ixv-610">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;2.02</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;18, 2025, Delcath Systems, Inc. (&#8220;Delcath&#8221;) issued a press release announcing preliminary financial results for the quarter ended September&#160;30, 2025. A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section nor shall it be incorporated by reference into any other filing by Delcath with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;) whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing. </span></p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;18, 2025, Delcath issued a press release announcing, among other things, updated 2025 full year revenue guidance. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference in this Item 7.01. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities of that section nor shall it be incorporated by reference into any other filing by Delcath with the Commission whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing. </span></p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">CHOPIN Trial </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;18, 2025, Delcath issued a press release announcing the results of the CHOPIN Trial. A copy of the press release is furnished as Exhibit 99.2. The CHOPIN Trial was designed to compare the safety, tolerability and efficacy of Delcath&#8217;s CHEMOSAT<sup style="font-size:75%; vertical-align:top">&#174;</sup> Hepatic Delivery System (&#8220;HDS&#8221;) with melphalan for percutaneous hepatic perfusion (&#8220;PHP&#8221;) when used alone versus when combined with the systemic immune checkpoint inhibitors (&#8220;ICI&#8221;) ipilimumab and nivolumab. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CHOPIN Trial randomized 1:1 76 patients with metastatic uveal melanoma (&#8220;mUM&#8221;) to receive PHP alone at weeks one and seven (the &#8220;PHP group&#8221;) or four cycles of ipilimumab (1 mg/kg) and nivolumab (3 mg/kg) every three weeks over approximately nine weeks with two PHP treatments at weeks one and seven (the &#8220;combination group&#8221;). Once the nine-week treatment period was completed patients were monitored until progression. Key eligibility criteria included unresectable hepatic metastases with 50% or less unresectable disease and limited extrahepatic disease. The primary endpoint was <span style="white-space:nowrap">one-year</span> progression-free survival; secondary endpoints included safety, best overall response rate, overall survival, and hepatic progression-free survival. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key results from the CHOPIN Trial were as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left"><span style="font-weight:bold">&#8226;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:left">Progression-Free Survival (95% CI): </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">One Year % (95% CI) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Combination group: 54.7% (36.8 - 69.5) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">PHP group: 15.8% (5.8 - 30.1) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Median months (95% CI) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Combination group: 12.8 (9.2 - 15.4) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">PHP group: 8.3 (6.0 - 9.6) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Hazard Ratio 0.34 (0.19 - 0.60) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">P&lt;0.001 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left"><span style="font-weight:bold">&#8226;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:left">Overall Survival - (95% CI): </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">One Year % (95% CI) </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Combination group: 82.8% (65.6 - 91.9) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">PHP group: 82.2% (64.5 - 91.6) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Two Year % (95% CI) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Combination group: 49.6% (29.3 - 67.0) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">PHP group: 22.1% (7.9 - 40.6) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Median: months (95% CI) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Combination group: 23.1 (20.2 - 38.5) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">PHP group: 19.6 (15.2 - 21.8) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Hazard Ratio: 0.39 (0.20 - 0.77) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">P = 0.006 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left"><span style="font-weight:bold">&#8226;</span></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:left">Best Overall Response Rate (95% CI): </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Combination group: 76.3 (59.4 - 88.0) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">PHP group: 39.5 (24.5 - 56.5) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">P &lt; 0.001 </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preliminary Third Quarter Financial Results (unaudited) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;18, 2025, Delcath also announced the following preliminary unaudited third quarter ended September&#160;30, 2025, financial and operational results: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Total CHEMOSAT and HEPZATO KIT revenue of approximately&#160;$20.5&#160;million </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HEPZATO KIT<sup style="font-size:75%; vertical-align:top">&#8482;</sup> revenue of $19.2&#160;million </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">CHEMOSAT<sup style="font-size:75%; vertical-align:top">&#174;</sup> revenue of $1.3&#160;million </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Gross margins expected to be 87% </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Net income of $0.8&#160;million </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Positive adjusted EBITDA of $5.3&#160;million </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Positive operating cash flow of approximately $4.8&#160;million </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2025, Delcath had approximately $88.9&#160;million of cash, cash equivalents and short-term investments and no debt. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preliminary and Unaudited Nature of Preliminary Third Quarter Financial Results </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preliminary estimated financial results for the quarter ended September&#160;30, 2025, included in this Current Report on Form <span style="white-space:nowrap">8-K</span> are preliminary, unaudited and have not been reviewed by Delcath&#8217;s independent auditors and are subject to completion of <span style="white-space:nowrap">quarter-end</span> financial and accounting procedures and may change as a result of management&#8217;s continued review. The preliminary financial results represent management estimates that constitute forward-looking statements subject to risks and uncertainties. As a result, the preliminary financial results may materially differ from the actual results when they are completed and publicly disclosed. The preliminary financial results are not a comprehensive statement of all financial results for the quarter ended September&#160;30, 2025. Subsequent information or events may lead to material differences between the foregoing preliminary financial results and those reported in Delcath&#8217;s subsequent filings with the Commission. Accordingly, investors should not place undue reliance on these preliminary financial results. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">GAAP v. <span style="white-space:nowrap">Non-GAAP</span> Measures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the financial information presented in this Current Report on Form <span style="white-space:nowrap">8-K</span> in accordance with accounting principles generally accepted in&#160;the United States of America&#160;(GAAP), Delcath also presents adjusted <span style="white-space:nowrap">non-GAAP</span> financial measures. Delcath&#8217;s management believes that the <span style="white-space:nowrap">non-GAAP</span> adjusted EBITDA described in this Current Report on Form <span style="white-space:nowrap">8-K,</span> which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Delcath&#8217;s underlying performance, business and performance trends, and helps facilitate <span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> comparisons and comparisons of its financial measures with other companies in Delcath&#8217;s industry. However, the <span style="white-space:nowrap">non-GAAP</span> financial measures that </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Delcath uses may differ from measures that other companies may use. <span style="white-space:nowrap">Non-GAAP</span> financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath does not provide guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between its forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net income and the respective reconciliations. These forecasted items are not within Delcath&#8217;s control, may vary greatly between periods, and could significantly impact future financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by Delcath or on its behalf. This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements, including statements regarding Delcath&#8217;s 2025 full-year revenue guidance, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: Delcath&#8217;s commercialization plans and its ability to successfully commercialize the HEPZATO KIT; contributions to adjusted EBITDA; Delcath&#8217;s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of Delcath and those of its third-party suppliers/manufacturers; Delcath&#8217;s successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; Delcath&#8217;s ability to obtain reimbursement for the HEPZATO KIT; and Delcath&#8217;s ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact Delcath, please see Delcath&#8217;s filings with the&#160;Securities and Exchange Commission, including those on Forms <span style="white-space:nowrap">10-K,</span> <span style="white-space:nowrap">10-Q,</span> and <span style="white-space:nowrap">8-K.</span> However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made. </span></p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d51469dex991.htm">Press Release (Preliminary Financial Results), dated&#160;October&#160;18, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d51469dex992.htm">Press Release (CHOPIN Trial results), dated&#160;October&#160;18, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:42%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">DELCATH SYSTEMS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: October&#160;20, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#8195;&#8195;By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gerard Michel</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#8195;&#8195;Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Gerard Michel</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#8195;&#8195;Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d51469dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51469g41r30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;18, 2025 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>Conference
Call October&nbsp;20, 8:45am EST</I></B><B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QUEENSBURY, N.Y.&#8212;(BUSINESS WIRE)&#8212;Oct. 18, 2025&#8212; Delcath Systems, Inc. (NASDAQ: DCTH),
an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September&nbsp;30, 2025, and updated 2025 full-year revenue guidance.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary Third Quarter Financial Results (unaudited) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5&nbsp;million </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HEPZATO KIT revenue of $19.2&nbsp;million </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHEMOSAT revenue of $1.3&nbsp;million </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gross margins expected to be 87% </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net income of $0.8&nbsp;million </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Positive adjusted EBITDA of $5.3&nbsp;million </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Positive operating cashflow of approximately $4.8&nbsp;million </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2025, the Company had approximately $88.9&nbsp;million of cash, cash equivalents and short-term investments and no debt. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2025 Full Year Financial Guidance </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Total CHEMOSAT and HEPZATO KIT revenue of $83&nbsp;million to $85&nbsp;million, reflecting an approximate 150%
increase in treatment volume over 2024 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly gross margins between 85% to 87% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Positive adjusted EBITDA and operating cashflow in each quarter of 2025 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Although our third quarter revenue was modestly lower than the second quarter, this decline was primarily due to the NDRA discounts and unexpected
summer seasonality which impacted the scheduling of new patient starts,&#8221; said Gerard Michel, Chief Executive Officer of Delcath Systems. &#8220;We are confident that we will achieve strong growth in 2026 and beyond. This expectation is based
on our ongoing expansion of active treatment centers and the positive influence of the CHOPIN trial results, which have demonstrated impressive efficacy and offer practical advantages for initiating patients on systemic therapy, while preparing for
PHP therapy.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath Systems, Inc. will host a conference call and webcast on October&nbsp;20, 2025, at 8:45 a.m. Eastern Time to discuss the Phase 2 CHOPIN Trial results
and provide a brief overview of the financial results announced in this release. Joining Delcath management on the call with <FONT STYLE="white-space:nowrap">pre-recorded</FONT> remarks will be Dr.&nbsp;Vincent&nbsp;T. Ma, Assistant Professor and
Medical Oncologist at the University of Wisconsin Department of Medicine, a current user of HEPZATO KIT for the treatment of metastatic uveal melanoma patients, an expert in treating cutaneous melanoma, and a
<FONT STYLE="white-space:nowrap">co-author</FONT> on the seminal Nature Medicine paper exploring liver immune tolerance mechanisms in cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To
participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Event Date: Monday, October&nbsp;20 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Time: 8:45 AM Eastern Time </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participant Numbers: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Toll Free: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-877-407-3982</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">International: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-201-493-6780</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Webcast: <U>https://viavid.webcasts.com/starthere.jsp?ei=1738867&amp;tp_key=6f3953dd75</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company&#8217;s website <U><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://investors.delcath.com/news-events/events-and-presentations</FONT></FONT></U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Delcath Systems, Inc., HEPZATO KIT, and CHEMOSAT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company&#8217;s proprietary
products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while
controlling systemic exposure and associated side effects during a PHP procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, HEPZATO KIT is considered a combination drug and
device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath&#8217;s proprietary HDS. The HDS is used to isolate the hepatic venous blood from the systemic
circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful
tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases
affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full <U>Prescribing Information</U>,
including BOXED WARNING for the HEPZATO KIT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Europe, the device-only configuration of the HDS is regulated as a Class&nbsp;III medical device and is
approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the
liver. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary Nature of Third Quarter Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preliminary estimated financial results for the quarter ended September&nbsp;30, 2025 included in this press release are preliminary, unaudited and have
not been reviewed by Delcath&#8217;s independent auditors and are subject to completion of <FONT STYLE="white-space:nowrap">quarter-end</FONT> financial and accounting procedures and may change as a result of management&#8217;s continued review. The
preliminary financial results represent management estimates that constitute forward-looking statements subject to risks and uncertainties. The preliminary financial results are not a comprehensive statement of all financial results for the quarter
ended September&nbsp;30, 2025. Subsequent information or events may lead to material differences between the foregoing preliminary financial results and those reported in Delcath&#8217;s subsequent SEC filings. Accordingly, investors should not
place undue reliance on these preliminary financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GAAP v. <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Measures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America
(GAAP), Delcath also presents adjusted <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures. Delcath&#8217;s management believes that the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> adjusted EBITDA described in this release,
which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Delcath&#8217;s underlying performance, business and performance
trends, and helps facilitate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparisons and comparisons of its financial measures with other companies in Delcath&#8217;s industry. However, the <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures that Delcath uses may differ from measures that other companies may use. <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures are not required to be uniformly applied, are
not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath does not provide guidance
for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between its forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates
for certain components of net income and the respective reconciliations. These forecasted items are not within Delcath&#8217;s control, may vary greatly between periods, and could significantly impact future financial results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Private Securities
Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, including the Company&#8217;s statements regarding the possible synergy
seen in the successful Phase 2 CHOPIN Trial being transferable to clinical practice; statements regarding the potential of CHEMOSAT Hepatic Delivery System and HEPZATO KIT to improve outcomes for patients with metastatic uveal melanoma; statements
regarding the potential to drive increased adoption of HEPZATO KIT; statements regarding the CHOPIN Phase 2 Trial results supporting the opening of new treatment sites, and accelerating the referral of mUM patients to treatment sites; statements
regarding Delcath&#8217;s continued growth and leadership in liver-directed oncology; and statements regarding Delcath&#8217;s 2025 full-year revenue guidance, , which are subject to certain risks and uncertainties, that can cause actual results to
differ materially from those described. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221;
&#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify
forward-</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>looking statements, although not all forward-looking statements contain these identifying words. Factors
that may cause such differences include, but are not limited to, uncertainties relating to: the Company&#8217;s commercialization plans and its ability to successfully commercialize the HEPZATO KIT; contributions to adjusted EBITDA; the
Company&#8217;s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and
those of its third-party suppliers/manufacturers; the Company&#8217;s successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with
primary and metastatic disease in the liver; the Company&#8217;s ability to obtain reimbursement for the HEPZATO KIT; and the Company&#8217;s ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO
KIT. For additional information about these factors, and others that may impact the Company, please see the Company&#8217;s filings with the Securities and Exchange Commission, including those on Forms <FONT STYLE="white-space:nowrap">10-K,</FONT> <FONT
STYLE="white-space:nowrap">10-Q,</FONT> and <FONT STYLE="white-space:nowrap">8-K.</FONT> However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you
should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the
date they are made. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains forward-looking statements, including statements regarding the expected release of clinical trial results,
which are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, delays in the presentation of the data, or other unforeseen issues relating to the release of the clinical
trial results. For a detailed discussion of these and other risks, please refer to Delcath&#8217;s filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">View source version on
<U>businesswire.com</U>: <U>https://www.businesswire.com/news/home/20251018070634/en/</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ICR Healthcare </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investorrelations@delcath.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Delcath Systems, Inc. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d51469dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51469g41r30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;18, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Conference Call
October&nbsp;20, 8:45am EST </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QUEENSBURY, N.Y.&#8212;(BUSINESS WIRE)&#8212;Oct. 18, 2025&#8212; Delcath Systems, Inc. (NASDAQ: DCTH), an
interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author
Professor Ellen Kapiteijn, MD, from Leiden University Medical Center&#8217;s Department of Medical Oncology at the 2025 European Society of Medical Oncology (ESMO) Annual Congress. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHOPIN Trial Design </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The investigator-initiated,
prospective, randomized Phase 2 CHOPIN Trial was designed to compare the safety, tolerability, and efficacy of Delcath&#8217;s CHEMOSAT <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Hepatic Delivery System (HDS) with melphalan for
percutaneous hepatic perfusion (PHP) when used alone versus when combined with the systemic immune checkpoint inhibitors (ICI) ipilimumab and nivolumab. Patients with metastatic uveal melanoma (mUM) were randomized 1:1 to receive PHP alone or in
combination with ipilimumab and nivolumab. CHEMOSAT is the device component of the U.S. Food and Drug Administration (FDA) approved combination drug and device product HEPZATO KIT<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (HEPZATO
(melphalan) for Injection/Hepatic Delivery System). HEPZATO KIT is approved for the liver-directed treatment of adult patients with uveal melanoma with unresectable hepatic metastases with less than 50% liver involvement and is administered every
six to eight weeks for up to six melphalan/HDS treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ipilimumab and nivolumab are approved by the FDA and European Union for the treatment of
unresectable metastatic melanoma, typically administered intravenously every three weeks for four doses, followed by maintenance nivolumab monotherapy every two to four weeks until disease progression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CHOPIN Trial randomized 76 patients 1:1 to receive PHP alone at weeks one and seven (PHP group) or four cycles of ipilimumab (1 mg/kg) and nivolumab (3
mg/kg) every three weeks over approximately nine weeks with two PHP treatments at weeks one and seven (combination group). The CHOPIN Trial design did not include additional PHP treatments beyond two treatments or nivolumab maintenance monotherapy.
Once the nine-week treatment period was completed patients were monitored until progression. Key eligibility criteria included unresectable hepatic metastases with 50% or less unresectable disease and limited extrahepatic disease. The primary
endpoint was <FONT STYLE="white-space:nowrap">one-year</FONT> progression-free survival; secondary endpoints included safety, best overall response rate, overall survival, and hepatic progression-free survival. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CHOPIN Trial Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Results from the CHOPIN
Phase 2 Trial: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Progression-Free Survival (95% CI): </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One Year % (95% CI) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combination group: 54.7% (36.8 - 69.5) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PHP group: 15.8% (5.8 - 30.1) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Median months (95% CI) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combination group: 12.8 (9.2 - 15.4) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PHP group: 8.3 (6.0 - 9.6) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hazard Ratio 0.34 (0.19 - 0.60) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">P&lt;0.001 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Overall Survival - (95% CI): </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One Year % (95% CI) </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combination grosaup: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PHP group: 82.2% (64.5 - 91.6) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Two Year % (95% CI) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combination group: 49.6% (29.3 - 67.0) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PHP group: 22.1% (7.9 - 40.6) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Median: months (95% CI) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combination group: 23.1 (20.2 - 38.5) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PHP group: 19.6 (15.2 - 21.8) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hazard Ratio: 0.39 (0.20 - 0.77) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">P = 0.006 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Best Overall Response Rate (95% CI):</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combination group: 76.3 (59.4 - 88.0) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PHP group: 39.5 (24.5 - 56.5) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">P &lt; 0.001 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grade 3 or higher treatment-related adverse events were more frequent in the combination group (81.6% vs. 40.5%, P&lt;0.001), but most were manageable with
standard care. Overall, the combination treatment was well tolerated, with types, rates and frequencies of adverse events consistent with individual use of PHP and checkpoint inhibitors. No new safety signals were identified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The abstract is available at <U>ESMO Congress 2025&#8212;Mini Oral Session LBA59</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;The CHOPIN trial clearly demonstrates that adding ipilimumab and nivolumab to PHP is both effective and tolerable. The efficacy results are impressive,
especially when considering the treatment regime included only two PHP treatments and did not include nivolumab maintenance. Since many oncologists start systemic therapy first, this approach provides valuable lead time for patient assessment and
scheduling PHP, helping to overcome logistical barriers and support broader adoption and near- to medium-term uptake,&#8221; said Gerard Michel, Chief Executive Officer of Delcath Systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of large, randomized clinical trials shows that patients with liver metastases typically have poorer outcomes than those with metastases elsewhere
when treated with ICIs across multiple tumor types, including melanoma, <FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung cancer (NSCLC), urothelial carcinoma, and renal cell carcinoma<SUP STYLE="font-size:75%; vertical-align:top">1</SUP><SUP
STYLE="font-size:75%; vertical-align:top">,</SUP> <SUP STYLE="font-size:75%; vertical-align:top">2</SUP>. This diminished efficacy of ICIs has been attributed to the well-documented immunosuppressive nature of the liver microenvironment, with
underlying mechanisms increasingly understood through preclinical and clinical research<SUP STYLE="font-size:75%; vertical-align:top">3</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;In
addition to the potential immediate benefit to patients with metastatic uveal melanoma, the possible synergy of PHP and ICI therapy seen in the successful Phase 2 CHOPIN trial may be transferable to other cancers with liver-dominant disease, and
Delcath looks forward to investigating that potential,&#8221; said Dr.&nbsp;Vojislav Vukovic, Chief Medical Officer of Delcath Systems. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference
Call Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath Systems, Inc. will host a conference call and webcast on October&nbsp;20, 2025, at 8:45 a.m. Eastern Time to discuss the
Phase 2 CHOPIN Trial results and provide a brief overview of the financial results and guidance announced in this release. Joining Delcath management on the call with <FONT STYLE="white-space:nowrap">pre-recorded</FONT> remarks will be
Dr.&nbsp;Vincent&nbsp;T. Ma, Assistant Professor and Medical Oncologist at the University of Wisconsin Department of Medicine, a current user of HEPZATO KIT for the treatment of metastatic uveal melanoma patients, an expert in treating cutaneous
melanoma, and a <FONT STYLE="white-space:nowrap">co-author</FONT> on the seminal Nature Medicine paper exploring liver immune tolerance mechanisms in cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Event Date: Monday, October&nbsp;20 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Time: 8:45 AM Eastern Time
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participant Numbers: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Toll Free: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-877-407-3982</FONT></FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">International: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-201-493-6780</FONT></FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Webcast:
<U>https://viavid.webcasts.com/starthere.jsp?ei=1738867&amp;tp_key=6f3953dd75</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A replay of the webinar will be available shortly after the conclusion
of the call and will be archived on the company&#8217;s website <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://investors.delcath.com/news-events/events-and-presentations</FONT></FONT></U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Delcath Systems, Inc., HEPZATO KIT, and CHEMOSAT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">De lcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company&#8217;s proprietary
products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while
controlling systemic exposure and associated side effects during a PHP procedure. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and
approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath&#8217;s proprietary HDS. The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously
filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal
hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver
and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full <U>Prescribing Information</U>, including BOXED WARNING for the
HEPZATO KIT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name
CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Private Securities
Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by Delcath or on its behalf. This press release contains forward-looking statements, including statements regarding the possible synergy seen in the successful
Phase 2 CHOPIN Trial being transferable to other cancers with liver-dominant disease; statements regarding the potential of CHEMOSAT Hepatic Delivery System and HEPZATO KIT to improve outcomes for patients with metastatic uveal melanoma and other
cancers with liver-dominant disease; statements regarding the potential to drive increased adoption of HEPZATO KIT; statements regarding Delcath&#8217;s commitment to raising awareness of the innovative approach taken in the CHOPIN Trial, and
accelerating the referral of patients to treatment sites; and statements regarding Delcath&#8217;s continued growth and leadership in liver-directed oncology, which are subject to certain risks and uncertainties, that can cause actual results to
differ materially from those described. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221;
&#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company&#8217;s commercialization plans and its ability
to successfully commercialize the HEPZATO KIT; contributions to adjusted EBITDA; the Company&#8217;s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and
assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company&#8217;s successful implementation and management of the HEPZATO KIT Risk Evaluation and
Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company&#8217;s ability to obtain reimbursement for the HEPZATO KIT; and the Company&#8217;s ability to
successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company&#8217;s filings with the Securities and
Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place
undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are
made. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains forward-looking statements, including statements regarding the expected release of clinical trial results, which are
subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, delays in the presentation of the data, or other unforeseen issues relating to the release of the clinical trial results.
For a detailed discussion of these and other risks, please refer to Delcath&#8217;s filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citations for footnotes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat
Med 27, 152&#8211;164 (2021) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Wang, F. et al. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Biomarker for Immune
Checkpoint Inhibitors Treatment Outcome. Front Oncol 11:691853 (2021). doi:10.3389/fonc.2021.691853 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Li, L. et al. Liver metastases and the efficacy of immune checkpoint inhibitors in patients with advanced lung
cancer: A retrospective study. Front Oncol 12:978069 (2022). doi:10.3389/fonc.2022.978069 </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">View source version on
<U>businesswire.com</U>: <U>https://www.businesswire.com/news/home/20251018759712/en/</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations Contact:</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ICR Healthcare </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investorrelations@delcath.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Delcath Systems, Inc. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>dcth-20251018.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/20/2025 7:49:56 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:dcth="http://www.delcath.com/20251018"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.delcath.com/20251018"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dcth-20251018_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dcth-20251018_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>dcth-20251018_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/20/2025 7:49:56 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>dcth-20251018_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/20/2025 7:49:56 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="dcth-20251018.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g51469g41r30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g51469g41r30.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "/ BH# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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ME06\WV>ZM+D 2P/C(! Z@@Y![\^AKP,;@JN!J>SJ]=@/1JX "@ H * "@ H
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M_0.&_P"#4]?T ^)*^P _5S_@G/\ \FUV/_81N_\ T.OS+/\ _?7Z(#Z?KYP
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MY%B<.N:G[Z\M_N_R ^I8I4GB22-UDC<!E=#D,#T(/<5\VU;1@/I % 'YO_\
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M'NRX#@?0-7B8CAVM#6A+F\GH_P#(#ZZ\'>.- ^(.B1:OX;U>TUG3I.D]I('
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M*S657@M-OF'>A7C<0.,^M>;F&%EC,/*C!V;[@?</_#T/X>_]"OXF_P"_=O\
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M9=_8MUSX\NFM:O/+H'@Y&P;I4S/=$=5A!X ]7.0/0U\]F6;T\%^[@N:?X+U
M_1SX:?LY?#SX36,<'A_PS9I,H&Z]NT$]PY]2[9(^BX'M7P&(Q^)Q3O4F_39
M>D@   # ':O/ S->\+Z/XILWM=9TJSU6V=2K17D"RJ0>O# UI"I.D[PDT_(#
MY*^.W_!.;POXMMKG4_A_+_PC6LX+C3Y6+V<Q]!G+1D^H)'L*^HP6?U:34<1[
MT>_7_@@?/GPE_P""?OQ#U;XE6EGXRT<:/X:M)EDO+P7,;BXC'.R+:226QC)
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M@% !0 4 % !0!Q_QC_Y)%XW_ .P'??\ HAZZL)_O%/\ Q+\P/PTK]F ]A_9
M_P"3E_A__P!A#_VF]>3FO^Y5?0#]FJ_)0"@ H * "@ H * /S._X*>>($OOB
M]X>TF-MWV'2%>0?W7>60X_[Y"G\:_0^'*=L/*;ZO] /C6OK0/TT_X)B:%]A^
M#WB#4R3NOM7*@'IM2-!_,FOSOB.?-B8Q[(#T3]O#7I="_9I\2"*1HFO7AM"5
M."0SY(_$+7GY+!3QL+]-0/R'K]4 [[X)?&#4?@;XYA\4Z58VE_?10R0I'> E
M '&">".:X<9A(XVE[*;L@/HK_AY[\0/^A<T+\I?_ (JO!_U<P_\ .P#_ (>>
M_$#_ *%S0ORE_P#BJ/\ 5S#_ ,[ /^'GOQ _Z%S0ORE_^*H_U<P_\[ /^'GO
MQ _Z%S0ORE_^*H_U<P_\[ J:O_P4K\>:SI5Y83>'=#$-U"\#E1)G:RD'^+T-
M5'A[#PDI*3T ^0J^J ]>_9%O&L?VE/A_*IP3J0C_  =&4_HU>5FJYL%57D!^
MSM?D@'YO_P#!4G_DHG@S_L%/_P"CFK] X;_@U/7] /B2OL /U<_X)S_\FUV/
M_81N_P#T.OS+/_\ ?7Z(#Z?KYP#\[?\ @J7XDEF\3^!M #XAM[2XO60=VD=4
M!/T$9_,U]YPU32A4J=VE_7W@?"U?: ?I/_P2_P#!D6G_  U\3^)WB47.I:D+
M-)".?*A0'CVW2M^5?GW$=9RKPI=$K_?_ ,,!]J5\@!R'Q7\9_P#"!^!=2U5"
M/M*KY< /_/1N%_+K^%=F$H?6*RAT/!SO,?[,P,\0OBV7J]CX6FNYK^ZEN;B1
MIIY7+O(YR68G))-?932BK+8_G/VDJLG.;NV[LECZUYM0[:9<A)4Y!P0>M>;4
M/2IGN'PP^/\ <>'[6+3=>62]LD^6*Y7F2-?0_P!X5Y51).Y^@Y3G\J,51Q.L
M>CZK_,]NT[XH>%=3A\V+7+- !DK-((V'X'%8<R74^XIYEA*JO&HOOL<[XG^/
M&@:1"RZ<_P#:MR1\HBXC'U;_  KGJ8B,%IJ<E?-\/35J;YG^!X/XB\4ZAXNU
M22^U"8R2'A4'W47T4=A7SF(J2JN\CYJIB*F)GSU&58^M>/4-Z9:CZUYM0]&F
M>D_!OQ')IGB)=/=S]EO05VGH' )4_P Q^->IDN*='$JBW[LOS/8PTK.Q[U7Z
M&>D9?B?0[?Q-X<U32;M/,MKVVDMY%]0RD?UK2G-TYJ:W3 _"GQ%I+:#X@U/3
M'.6LKJ6V)/JCE?Z5^T4Y<\%+N@+O@/Q#)X3\;:%K4+%9;"]AN5*]05<'^E17
MIJK2E!]4!^[44JSQ)(AW(ZAE([@]*_%VK: ><?M*_P#) O'W_8'N/_037?E_
M^]TO5 ?B=7[ !]&?\$__ /DYSP]_U[W/_HHUX&>?[C+Y?F!^M]?EP!0 4 ?(
M?_!3K_D@6B?]C';_ /I-<U]3PY_O<O\ "_S0'Y@5^C@?67_!-SP%%XH^.%WK
M=S&LD.@6#3Q[ESB:0[$/UV^8?PKY?B"NZ>%5-?:?X(#]2:_-P"@ H * /FC_
M (*'V*7?[,NKRL2&MKZTE7'<F4+C\F-?0Y#*V.BNZ8S\FZ_3Q'W#_P $M/\
MD>/&_P#V#H?_ $;7QO$O\*GZO\@/T:KX$ H * "@ H * ./^,?\ R2+QO_V
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M*_1P/T#_ ."5EE&+3XCW>T&8O81!O10)SC]?TKX;B63O2CZ_H!]\5\0 4 %
M!0!\X_\ !07_ )->\1?]?-G_ .E"5[^1?[]#Y_D!^25?J('W#_P2T_Y'CQO_
M -@Z'_T;7QO$O\*GZO\ (#]&J^! * "@ H * "@#C_C'_P DB\;_ /8#OO\
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M * "@ H * .0^,*E_A)XV502QT2]  [_ +AZZL+_ +Q3_P 2_,#\,Z_9@"@
MH * "@ H * /1?A;^S]X\^,=XD7AGP_=7=N6 >^D7R[:/_>D;"_AG-<&)QV'
MPBO5E9]NOW ??G[/G_!/KPY\.)[36_&4T7B;7(\.MKL_T2%OH?OD'N>/:OA\
M?GM7$7A1]V/X@?6\420QK'&BQQH JJHP !T %?+;[@/H * "@!" 001D'L:
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M,0%>L8ZG81D^H8GHM?.83/8U\2Z<U:+V]?/U ^-B"I((P1P0:^M 2@#]&?\
M@EK>3R^#?'-L\C-!#>6S1H3PI9)-V/KM'Y5\#Q(DJM-^3 ^@_P!I;]G?2OVA
MO YTRX9++6+4F73]0*9,;X^ZW?8>X^AKPLOQ\\!5YUJGN@/R5^*7PD\3_!WQ
M/<:'XFTV6RN(V/E3%3Y5PF>'C;HRGV^AYK]0PV*I8N"J4G<#C:ZP"@#];?\
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MP:XN[R7S)I<= 2   ,G@ 5Y&,Q];'24JKV[ >F5YP!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
< !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000872912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 18,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DELCATH SYSTEMS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1245881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">566 Queensbury Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Queensbury<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">12804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">489-2100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DCTH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d51469d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d51469d8k.htm">d51469d8k.htm</File>
    <File>dcth-20251018.xsd</File>
    <File>dcth-20251018_lab.xml</File>
    <File>dcth-20251018_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d51469d8k.htm": {
   "nsprefix": "dcth",
   "nsuri": "http://www.delcath.com/20251018",
   "dts": {
    "inline": {
     "local": [
      "d51469d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "dcth-20251018.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "dcth-20251018_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dcth-20251018_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-10-18_to_2025-10-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d51469d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-10-18_to_2025-10-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d51469d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.delcath.com//20251018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-25-242909-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-242909-xbrl.zip
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M,OEZXGLOM0.;E5KAM-YJEZK@2&T7AWX#5*6^_@_?M:KFT;$@(7-9@ 0@GJ1
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M(C/]+0\V@SU_J&0Q<Z;#B N6-+<T/]C2(Q7-@5CZ)VG&UQ010<0!7SH-FJ"
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M:C1R+,97N1B+OL%)>>C;,[@&[],]_3]02P,$%     @ ,S!46W[XOT"(%0
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M+BH2BCA!SF'52\J]:115 =A2.<E37#8 Q[;67GB)6#_@&I7J&V3N-PDUE?#
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M<=MZV&[.TZ1)B[W1G,'<V3)^A#M#W)0A7( ;.9EN6E35Q9G/?.."B\4L+I8
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M[UBK4W85!9+<HK:EPX+<DK*Y+L\=5"&$2ZA*!G#'VC&!BKQ3=1+V=R  %XU
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M"[IFC"@R1H]M<4B3M!I8 _KS<(%&JXV&TFQ 4 PSG!WH'>PDA"'DXB$!UU@
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M\WP586_I'=8$-!LP&_I8Y,E)+G/4NA+,QC>$VHANP"M6 [4A^6#C(^D3$3;
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M75[Q%-(@^+*U!V&NW2+,-P^;NSO(T]!Z]/<6UD=?7P1^K;\@_#Y!=E1C[W,
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M'_8-0"SY"U!+ 0(4 Q0    ( #,P5%M7B"SYSAT  .3A   -
M  "  0    !D-3$T-CED.&LN:'1M4$L! A0#%     @ ,S!46W[XOT"(%0
M^E0  !               ( !^1T  &0U,30V.61E>#DY,2YH=&U02P$"% ,4
M    "  S,%1;-AF@.H89  !EA   $               @ &O,P  9#4Q-#8Y
M9&5X.3DR+FAT;5!+ 0(4 Q0    ( #,P5%O%.L,2/0,  $@+   1
M      "  6--  !D8W1H+3(P,C4Q,#$X+GAS9%!+ 0(4 Q0    ( #,P5%LD
M)&U_808  +U#   5              "  <]0  !D8W1H+3(P,C4Q,#$X7VQA
M8BYX;6Q02P$"% ,4    "  S,%1;"1VTC+H$  !Y*@  %0
M@ %C5P  9&-T:"TR,#(U,3 Q.%]P<F4N>&UL4$L%!@     &  8 ? $  %!<
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d51469d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dcth-20251018.xsd" xlink:type="simple"/>
    <context id="duration_2025-10-18_to_2025-10-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872912</identifier>
        </entity>
        <period>
            <startDate>2025-10-18</startDate>
            <endDate>2025-10-18</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2025-10-18_to_2025-10-18"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-581">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-10-18_to_2025-10-18"
      id="Hidden_dei_EntityCentralIndexKey">0000872912</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-592">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-593">2025-10-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-594">DELCATH SYSTEMS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-595">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-596">001-16133</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-597">06-1245881</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-598">566 Queensbury Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-599">Queensbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-600">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-601">12804</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-602">(212)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-603">489-2100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-604">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-605">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-606">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-607">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-608">Common Stock, $.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-609">DCTH</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-10-18_to_2025-10-18" id="ixv-610">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
